-
Severe psoriasis--oral therapy with a new retinoid.
Ro 10-9359 is a retinoic acid derivative, selected for study because of a better tolerance than retinoic acid, shown in animal experiments. Doses of 25 mg b.i.d., 25 mg t.i.d. and 50 mg b.i.d. were administered orally to 27 patients suffering from severe chronic generalized psoriasis. The clinical efficacy was evaluated by means of a new index, psoriasis area and severity index (PASI) based on severity and area of psoriatic lesions. At doses of 25 mg t.i.d. or 50 mg b.i.d. Ro 10--9359 proved to be an extremely potent antipsoriatic drug. A more than 90% reduction of psoriatic lesions could be seen in 10 patients out of 20 after 4-8 weeks of treatment. This good effect lasted about 5 weeks after treatment. Side effects were frequent, but mostly mild and completely reversible after termination of treatment.
PMID: 357213 [PubMed - indexed for MEDLINE]
-
Cited by 36 PubMed Central articles
-
Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study).
Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V.
BMJ. 2009 May 7; 338:b1542. Epub 2009 May 7.
[BMJ. 2009]
-
MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage.
Tan YM, Østergaard M, Doyle A, Dalbeth N, Lobo M, Reeves Q, Robinson E, Taylor WJ, Jones PB, Pui K, et al.
Arthritis Res Ther. 2009; 11(1):R2. Epub 2009 Jan 6.
[Arthritis Res Ther. 2009]
-
Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.
Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN, Worthington J, Griffiths CE.
Br J Dermatol. 2009 Feb; 160(2):438-41. Epub 2008 Oct 25.
[Br J Dermatol. 2009]
- » See all...